XERS Q2 2020 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$982M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+533.4% YoY

Gross Profit

$728,00035.9% margin

Operating Income

-$22M-1095.5% margin

Net Income

-$24M-1188.9% margin

EPS (Diluted)

$-0.63

QoQ Revenue Growth

+13.4%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$166M

Total Liabilities

$141M

Stockholders' Equity

$24M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$320,000	+533.4%
Gross Profit	$728,000	$297,000	+145.1%
Operating Income	-$22M	-$34M	+34.8%
Net Income	-$24M	-$34M	+29.9%